Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3a open-label single-arm study of N8-GP in previously untreated children with severe hemophilia A
MOH_2017-06-06_000491Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of octocog alfa in hemophilia A, sponsored by Novo Nordisk. Primary endpoints: Safety and immunogenicity and Efficacy for prophylaxis and treatment of bleeding episodes. Started Apr 2014; status: completed.
02
Drugs
octocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on MOH_2017-06-06_000491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-06_000491.